Despite the great concern of the European Agency for Medicines (EMA, for its acronym in English) by increasing Coronavirus cases on the continent and by the irruption of the omicron variant in many countries, the message that launches seeks not to be Alarmist: It is necessary to stop the progress of the new variant but it is still early to know how it affects the effectiveness of the vaccine and if it will be necessary to modify its composition. This has been manifested Marco Cavaleri, head of the EMA vaccine strategy, during an appearance held this Thursday in which the main novelties have been analyzed around the pandemic.
In this sense, Cavaleri has exposed that it is already working with the laboratories to analyze and measure how the variant omicron affects the vaccines currently available in order to, in a few months, be able to adapt any variation that is necessary; as well as to be able to develop a potential vaccine against this variant. In addition, he has pointed out that although the preliminary data show that the omicron variant can be "more transmissible" than the delta, more information must have to know how it affects the severity of the disease.
Together with this, the person responsible for EMA has influenced that vaccination is the "key" against Coronavirus and has insisted on the need to enhance the reinforcement doses. On this, he has expressed that it could be coherent that the states on the time interval between the second dose and the three-month reinforcement (instead, as it is currently recommended), since it would be "safe and effective", according to The data that is currently available.Date Of Update: 09 December 2021, 11:30